||The examples and perspective in this article deal primarily with the United States and do not represent a worldwide view of the subject. (February 2011)|
|Licence data||US FDA:|
|Legal status||Schedule II (US)|
|(what is this?)|
The combination oxycodone/paracetamol (North American trade name Percocet, generic endocet and ratio-oxycocet in Canada) is a narcotic pain reliever used to treat moderate to severe acute (short-term) pain, marketed by Endo Pharmaceuticals. It is regulated as a schedule 2 narcotic by the Drug Enforcement Agency (DEA) of the United States.
As of March 2006, Endo Pharmaceuticals produces Percocet in following dosages. Percocet tablets are available in six combinations of oxycodone hydrochloride and acetaminophen, with different appearances and maximum daily doses:
|Oxycodone Hydrochloride (mg)||Acetaminophen (mg)||Tablet Color||Tablet Shape||Maximum Daily Dose|
For the 2.5 mg Oxycodone HCl tablet, the usual dose is 1–2 tablets every six hours as needed for pain; for the other tablets, the usual dose is 1-2 tablets every four to six hours as needed for pain.
Implicated in deaths
On June 30, 2009, an FDA advisory panel recommended that Percocet, Vicodin, and every other combination of acetaminophen with narcotic analgesics be limited in their sales because of their contributions to an alleged 400 acetaminophen related deaths in the United States each year, that were attributed to acetaminophen overdose and associated liver damage.
In December 2009, the Canadian Medical Association Journal reported a study finding a fivefold increase in oxycodone-related deaths in Ontario (mostly accidental) between 1991 and 2007 that led to a doubling of all opioid-related Ontario deaths over the same period.
- "Drugs@FDA. FDA approved drug products (searchable database)". U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Retrieved 2009-03-30.
- "Percocet oxycodone and acetaminophen tablets USP". Endo Pharmaceuticals. May 2011. Retrieved October 20, 2012.
- Harris, Gardiner (2009-07-01). "Ban Is Advised on 2 Top Pills for Pain Relief". The New York Times. Retrieved 2010-05-22.
- Irfan A. Dhalla, Muhammad M. Mamdani, Marco L.A. Sivilotti, Alex Kopp, Omar Qureshi, David N. Juurlink. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. Canadian Medical Association Journal, 2009; 181 (12): 891 DOI: 10.1503/cmaj.090784
- Benedikt Fischer, Jürgen Rehm. Deaths related to the use of prescription opioids. Canadian Medical Association Journal, 2009; Fischer, B.; Rehm, J. (2009). "Deaths related to the use of prescription opioids". Canadian Medical Association Journal 181 (12): 881–882. doi:10.1503/cmaj.091791. PMC 2789122. PMID 19969577.
- Canadian Medical Association Journal (2009, December 7). Deaths from opioid use have doubled; five-fold increase in oxycodone deaths. ScienceDaily. Retrieved May 31, 2012, from http://www.sciencedaily.com/releases/2009/12/091207123105.htm